Press release, Helsinki, 19 December 2024 at 10 AM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS 6 system from a hospital customer in California, United States.
Launched in 2023 in the United States and Europe, the NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-approved for the treatment of major depressive disorder (MDD), as well as CE-marked for the treatment of MDD and chronic unilateral neuropathic pain. Nexstim’s systems are based on the company’s unique navigated transcranial magnetic stimulation (nTMS) technology.
Mikko Karvinen, CEO of Nexstim, comments: “Developing and releasing the NBS 6 has been one of the key projects of our strategy period that comes to an end in a couple of weeks. We are happy with how the sales processes have progressed with the new product in 2023 and 2024, and look forward to continuing the work also with the planned release of the diagnostics applications next year.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com